Largest pharmaceutical companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 44 pharmaceutical companies in the United States ranked by net assets, at AED 317.6B, ahead of Johnson & Johnson (AED 299.5B) and Merck & Co (AED 193.2B). Figures as of 19 Nov 2026, 23:47 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- PfizerAED 317.6B
- Median
- AED 2.4B
- Combined market value
- AED 13.72T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | AED 317.6B | AED 576.5B | AED 101.15 | 1.85% down | 15% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | AED 299.5B | AED 2.36T | AED 981.15 | 2.04% down | 34% up | ||
| 3 | Merck & CoMRK · Health Care | AED 193.2B | AED 1.2T | AED 487.78 | 3.61% down | 45% up | ||
| 4 | Abbott LaboratoriesABT · Health Care | AED 191.5B | AED 660.7B | AED 381.49 | 0.58% down | 16% down | ||
| 5 | Regeneron PharmaceuticalsREGN · Health Care | AED 114.8B | AED 350.8B | AED 3,391.24 | 2.35% down | 28% up | ||
| 6 | Eli LillyLLY · Health Care | AED 97.5B | AED 4.42T | AED 4,962.39 | 2.29% down | 33% up | ||
| 7 | Vertex PharmaceuticalsVRTX · Health Care | AED 68.6B | AED 484.8B | AED 1,912.28 | 2.94% down | 27% up | ||
| 8 | Bristol-Myers SquibbBMY · Health Care | AED 67.8B | AED 438B | AED 214.27 | 2.05% down | 30% up | ||
| 9 | ViatrisVTRS · Health Care | AED 54B | AED 83.7B | AED 73.02 | 1.97% down | 99% up | ||
| 10 | Royalty PharmaRPRX · Health Care | AED 35.7B | AED 143B | AED 248.72 | 1.38% down | 79% up | ||
| 11 | United TherapeuticsUTHR · Health Care | AED 26.1B | AED 87.5B | AED 2,053.46 | 3.16% down | 22% up | ||
| 12 | Elanco Animal HealthELAN · Health Care | AED 24B | AED 48.3B | AED 96.56 | 1.54% down | 26% up | ||
| 13 | BioMarin PharmaceuticalBMRN · Health Care | AED 22.4B | AED 43.7B | AED 225.58 | 0.02% down | 17% up | ||
| 14 | ZoetisZTS · Health Care | AED 12.2B | AED 120.6B | AED 296.73 | 5.59% down | 26% down | ||
| 15 | Ligand PharmaceuticalsLGND · Health Care | AED 3.7B | AED 21.1B | AED 1,053.87 | 3.94% down | 50% up | ||
| 16 | Legend BiotechLEGN · Health Care | AED 3.7B | AED 11.5B | AED 59.13 | 0.92% down | 41% down | ||
| 17 | Praxis Precision MedicinesPRAX · Health Care | AED 3.2B | AED 31.9B | AED 1,141.87 | 1.87% up | 86% up | ||
| 18 | Alnylam PharmaceuticalsALNY · Health Care | AED 2.9B | AED 72.7B | AED 542.91 | 1.06% down | 66% down | ||
| 19 | Belite BioBLTE · Health Care | AED 2.8B | AED 22.5B | AED 554.67 | 3.33% down | 43% up | ||
| 20 | InsmedINSM · Health Care | AED 2.7B | AED 116.4B | AED 530.57 | 20.58% up | 40% down | ||
| 21 | Spyre TherapeuticsSYRE · Health Care | AED 2.6B | AED 34.1B | AED 358.58 | 3.77% down | 332% up | ||
| 22 | Summit TherapeuticsSMMT · Health Care | AED 2.4B | AED 31B | AED 38.82 | 0.67% up | 36% down | ||
| 23 | TG TherapeuticsTGTX · Health Care | AED 2.4B | AED 36B | AED 238.29 | 1.88% down | 117% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | AED 2.4B | AED 26.1B | AED 238.66 | 4.15% down | 10% down | ||
| 25 | Cogent BiosciencesCOGT · Health Care | AED 2.3B | AED 17.7B | AED 101.88 | 0.25% down | 20% down | ||
| 26 | Protagonist TherapeuticsPTGX · Health Care | AED 2.3B | AED 29.7B | AED 455.50 | 2.47% down | 51% up | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | AED 2.2B | AED 33.8B | AED 1,457.15 | 0.34% down | 27% down | ||
| 28 | Edgewise TherapeuticsEWTX · Health Care | AED 1.9B | AED 16.6B | AED 151.21 | 0.48% down | 86% up | ||
| 29 | Dianthus TherapeuticsDNTH · Health Care | AED 1.8B | AED 17.5B | AED 311.56 | 1.01% up | 108% up | ||
| 30 | Ionis PharmaceuticalsIONS · Health Care | AED 1.8B | AED 16.7B | AED 99.97 | 0.62% down | 63% down | ||
| 31 | Oruka TherapeuticsORKA · Health Care | AED 1.7B | AED 24.3B | AED 358.36 | 1.91% up | 255% up | ||
| 32 | Arrowhead PharmaceuticalsARWR · Health Care | AED 1.7B | AED 22.7B | AED 160.32 | 1.25% up | 13% up | ||
| 33 | Definium TherapeuticsDFTX · Health Care | AED 1.2B | AED 14.8B | AED 108.27 | 1.24% up | 168% up | ||
| 34 | ErascaERAS · Health Care | AED 1.2B | AED 18.3B | AED 52.23 | 3.34% up | 395% up | ||
| 35 | Mirum PharmaceuticalsMIRM · Health Care | AED 1.2B | AED 22.9B | AED 350.79 | 3.27% up | 34% up | ||
| 36 | Rhythm PharmaceuticalsRYTM · Health Care | AED 510.8M | AED 29.7B | AED 428.98 | 1.88% down | 18% up | ||
| 37 | Travere TherapeuticsTVTX · Health Care | AED 421.7M | AED 17B | AED 177.40 | 3.86% down | 45% up | ||
| 38 | Axsome TherapeuticsAXSM · Health Care | AED 324.3M | AED 26.2B | AED 498.33 | 1.25% up | 6% down | ||
| 39 | Amneal PharmaceuticalsAMRX · Health Care | -AED 260M | AED 27.4B | AED 78.56 | 2.24% down | 90% up | ||
| 40 | VeradermicsMANE · Health Care | -AED 444.5M | AED 19.3B | AED 456.86 | 0.38% down | 231% up | ||
| 41 | PTC TherapeuticsPTCT · Health Care | -AED 754.1M | AED 17.9B | AED 214.22 | 3.16% down | 21% down | ||
| 42 | CytokineticsCYTK · Health Care | -AED 2.4B | AED 26.3B | AED 189.00 | 0.27% up | 19% down | ||
| 43 | BridgeBio PharmaBBIO · Health Care | -AED 7.7B | AED 55.9B | AED 287.14 | 0.22% up | 21% up | ||
| 44 | AbbVieABBV · Health Care | -AED 12B | AED 1.84T | AED 1,041.39 | 0.86% down | 25% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED).
Questions and answers
Which pharmaceutical companies in the United States rank first by net assets?
Pfizer (AED 317.6B), Johnson & Johnson (AED 299.5B) and Merck & Co (AED 193.2B) are the top three of the 44 pharmaceutical companies in the United States ranked by net assets as of 19 Nov 2026, 23:47 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by net assets.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by net assets have a combined market value of AED 13.72T as of 19 Nov 2026, 23:47 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by net assets”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.